Multi-Disciplinary Organization Dedicated to Promoting Advances in
Neuro-Oncology Through Research and Education

Call for Abstracts - SNO 22nd Annual Scientific Meeting

Submission Deadline June 12, 2017

Read Full Story

SNO Pediatric Research Conference

June 15 - 16, 2017, New York, New York

Read Full Story

SNO Lifetime Achievement Award - Call for Nominations

Nomination Deadline June 19, 2017

Read Full Story
View All News

June
07

5th International CNS Germ Cell Tumor Symposium

Read Full Story

June
07

SIXTH ANNUAL WORLD COURSE IN ADVANCED BRAIN TUMOUR SURGERY

Read Full Story

June
15

Pediatric Neuro-Oncology Basic and Translational Research Conference

Read Full Story

Update - SNO International Outreach Fellow Dr. Jun-Pin Zhang

 

During the one year fellowship, Dr. Zhang attended both the adult neuro-oncology clinics at DFCI , as well as the pediatric neuro-oncology clinics at DFCI and Boston Children’s Hospital under the supervision of Drs. Mark Kieran and Susan Chi, to learn both the latest approaches to treating neuro-oncology patients, as well as learning how to conduct clinical trials. In addition, she attended the weekly Brain Tumor Board and neuro-oncology lectures. She also rotated through allied specialties including radiation oncology and neuropathology.

This fellowship was made possible by a generous grant from the American Brain Tumor Association and EMD Serono.

A major goal of her visit was to learn how to conduct clinical trials in neuro-oncology as there are relatively few trials currently in China. She completed Good Clinical Practice (GCP) and Collaborative Institutional Training Initiative (CITI) training for human subject protection in clinical research and met regularly with the research manager, clinical research coordinators and regulatory specialists in the Center For Neuro-oncology at DFCI. Over the course of the year she became familiar with the procedures involved with conducting clinical trials, as well as the laws, regulations and policies of clinical trials and protection of human subjects. She also helped in the development of a DFCI sponsored multicenter investigator initiated trial of the VEGFR/FGFR inhibitor nintedanib.

Dr. Zhang also conducted a clinical study during her time at DFCI evaluating the efficacy of pemetrexed in recurrent primary CNS lymphoma. This retrospective study of 18 primary CNS lymphoma patients (PCNSL) and 12 secondary CNS lymphoma (SCNSL) patients showed that the treatment was well-tolerated. The overall response rate for PCNSL was 64.7 %, all of whom achieved a complete response (CR) with a median progression-free survival (PFS) was 5.8 months. For SCNSL patients the response rate 58.3 % and the median PFS was 2.5 months. This study suggests that pemetrexed may have a role in recurrent PCNSL patients. This study was published in the Journal of Neuro-Oncology in 2013.(1)

Currently, Dr. Zhang Lin is working as neuro-oncologist at Sanbo Brain Hospital in Beijing, overseeing the care of a large number of both adult and pediatric brain tumor patients and providing chemotherapy.
 
Dr. Zhang is grateful to the Society for Neuro-Oncology, the American Brain Tumor Association and EMD Serono for their support in enabling this invaluable fellowship to occur.  During her time in the United States, Dr. Zhang benefitted from her exposure to both cutting edge clinical care and clinical research in neuro-oncology. She has returned to China better equipped to improve the care of brain tumor patients and help develop clinical trials for these patients.

1. Zhang JP, Lee EQ, Nayak L, Doherty L, Kesari S, Muzikansky A, Norden AD, Chen H, Wen PY, Drappatz J. Retrospective Study of Pemetrexed as Salvage Therapy for Central Nervous System Lymphoma. J Neuro-Oncol 2013 15(1):71-7.

 

 

 

 

 

 

Linda Greer
(281) 554-6589
(713) 583-1345
Author: Linda Greer
Phone: (281) 554-6589
Fax: (713) 583-1345
Email: